Literature DB >> 32894582

Race, APOL1 Risk Variants, and Clinical Outcomes among Older Adults: The ARIC Study.

Teresa K Chen1,2, Josef Coresh2,3, Natalie Daya2,3, Shoshana H Ballew2,3, Adrienne Tin4, Deidra C Crews1,2, Morgan E Grams1,2,3.   

Abstract

BACKGROUND/
OBJECTIVES: APOL1 high-risk genotypes confer an increased risk for kidney disease, but their clinical significance among older adults remains unclear. We aimed to determine whether APOL1 genotype status (high risk = 2 risk alleles; low risk = 0-1 risk alleles) and self-reported race (Black; White) are associated with number of hospitalizations, incident chronic kidney disease (CKD), end-stage renal disease (ESRD), and mortality among older adults participating in a community-based cohort study.
DESIGN: Observational longitudinal cohort study.
SETTING: The Atherosclerosis Risk in Communities (ARIC) study. PARTICIPANTS: Community-dwelling older adults (mean age = 75.8 years; range = 66-90 years).
RESULTS: Among 5,564 ARIC participants (78.2% White, 19.1% APOL1 low-risk Black, and 2.7% APOL1 high-risk Black), the proportion with creatinine and cystatin C-based estimated glomerular filtration rate (eGFRCrCys ) below 60 mL/min/1.73 m2 at baseline was 40.6%, 34.8%, and 43.2%, respectively. Over a mean follow-up of 5.1 years, APOL1 high-risk Blacks had a 2.67-fold higher risk for ESRD compared with low-risk Blacks (95% confidence interval [CI] = 1.05-6.79) in models adjusted for age and sex. This association was no longer significant upon further adjustment for baseline eGFRCrCys and albuminuria (hazard ratio [HR] = 1.08; 95% CI = .39-2.96). Rate of hospitalizations and risks of mortality and incident CKD did not differ significantly by APOL1 genotype status. Compared with Whites, Blacks had 1.85-fold and 3.45-fold higher risks for incident CKD and ESRD, respectively, in models adjusted for age, sex, eGFRCrCys , and albuminuria. These associations persisted after additional adjustments for clinical/socioeconomic factors and APOL1 genotype (incident CKD: HR = 1.38; 95% CI = 1.06-1.81; ESRD: HR = 3.20; 95% CI = 1.16-8.86).
CONCLUSION: Among older Black adults, APOL1 high-risk genotypes were associated with lower kidney function and therefore higher risk of ESRD. Racial disparities in incident kidney disease persisted in older age and were not fully explained by APOL1.
© 2020 The American Geriatrics Society.

Entities:  

Keywords:  APOL1; apolipoprotein L1; chronic kidney disease; end-stage renal disease; mortality

Mesh:

Substances:

Year:  2020        PMID: 32894582      PMCID: PMC7855571          DOI: 10.1111/jgs.16797

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  29 in total

1.  APOL1 variants associate with increased risk of CKD among African Americans.

Authors:  Meredith C Foster; Josef Coresh; Myriam Fornage; Brad C Astor; Morgan Grams; Nora Franceschini; Eric Boerwinkle; Rulan S Parekh; W H Linda Kao
Journal:  J Am Soc Nephrol       Date:  2013-06-13       Impact factor: 10.121

2.  Race, APOL1 Risk, and eGFR Decline in the General Population.

Authors:  Morgan E Grams; Casey M Rebholz; Yuan Chen; Andreea M Rawlings; Michelle M Estrella; Elizabeth Selvin; Lawrence J Appel; Adrienne Tin; Josef Coresh
Journal:  J Am Soc Nephrol       Date:  2016-03-10       Impact factor: 10.121

Review 3.  Social Determinants of Racial Disparities in CKD.

Authors:  Jenna M Norton; Marva M Moxey-Mims; Paul W Eggers; Andrew S Narva; Robert A Star; Paul L Kimmel; Griffin P Rodgers
Journal:  J Am Soc Nephrol       Date:  2016-05-13       Impact factor: 10.121

4.  The MYH9/APOL1 region and chronic kidney disease in European-Americans.

Authors:  Conall M O'Seaghdha; Rulan S Parekh; Shih-Jen Hwang; Man Li; Anna Köttgen; Josef Coresh; Qiong Yang; Caroline S Fox; W H Linda Kao
Journal:  Hum Mol Genet       Date:  2011-03-23       Impact factor: 6.150

5.  Estimating glomerular filtration rate from serum creatinine and cystatin C.

Authors:  Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey
Journal:  N Engl J Med       Date:  2012-07-05       Impact factor: 91.245

6.  Kidney Failure and ESRD in the Atherosclerosis Risk in Communities (ARIC) Study: Comparing Ascertainment of Treated and Untreated Kidney Failure in a Cohort Study.

Authors:  Casey M Rebholz; Josef Coresh; Shoshana H Ballew; Blaithin McMahon; Seamus P Whelton; Elizabeth Selvin; Morgan E Grams
Journal:  Am J Kidney Dis       Date:  2015-03-12       Impact factor: 8.860

7.  Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension.

Authors:  W McClellan; E Tuttle; A Issa
Journal:  Am J Kidney Dis       Date:  1988-10       Impact factor: 8.860

Review 8.  APOL1 kidney risk alleles: population genetics and disease associations.

Authors:  Sophie Limou; George W Nelson; Jeffrey B Kopp; Cheryl A Winkler
Journal:  Adv Chronic Kidney Dis       Date:  2014-09       Impact factor: 3.620

9.  Lifetime incidence of CKD stages 3-5 in the United States.

Authors:  Morgan E Grams; Eric K H Chow; Dorry L Segev; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2013-04-06       Impact factor: 8.860

10.  Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans.

Authors:  Michael S Lipkowitz; Barry I Freedman; Carl D Langefeld; Mary E Comeau; Donald W Bowden; W H Linda Kao; Brad C Astor; Erwin P Bottinger; Sudha K Iyengar; Paul E Klotman; Richard G Freedman; Weijia Zhang; Rulan S Parekh; Michael J Choi; George W Nelson; Cheryl A Winkler; Jeffrey B Kopp
Journal:  Kidney Int       Date:  2012-07-25       Impact factor: 10.612

View more
  1 in total

1.  Racial and Sex Disparities in Gout Prevalence Among US Adults.

Authors:  Natalie McCormick; Na Lu; Chio Yokose; Amit D Joshi; Shanshan Sheehy; Lynn Rosenberg; Erica T Warner; Nicola Dalbeth; Tony R Merriman; Kenneth G Saag; Yuqing Zhang; Hyon K Choi
Journal:  JAMA Netw Open       Date:  2022-08-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.